Allergy Therapeutics plc (LON:AGY - Get Free Report) was up 6.9% on Thursday . The stock traded as high as GBX 5.96 ($0.08) and last traded at GBX 5.88 ($0.07). Approximately 591,028 shares changed hands during trading, a decline of 15% from the average daily volume of 695,330 shares. The stock had previously closed at GBX 5.50 ($0.07).
Allergy Therapeutics Price Performance
The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The company's fifty day moving average price is GBX 5.05 and its 200-day moving average price is GBX 4.84. The stock has a market cap of £262.35 million, a P/E ratio of -86.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Further Reading
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
